Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth

Key Takeaways ANI Pharmaceuticals' rare disease revenues more than doubled to $291M in the first nine months.Cortrophin Gel sales rose 70% to $236M, supported by broader demand and expanded field efforts.ANIP cut its 2025 outlook for Iluvien and Yutiq but sees the franchise returning to growth in 2026.ANI Pharmaceuticals’ (ANIP) rare disease franchise has emerged as a major growth catalyst in 2025, with segment revenues more than doubling year over year to $291 million in the first nine months. The company ...